Antipsychotics in MDD Augmentation

CME

Recent Evidence for Treatment Augmentation With Second-Generation Antipsychotics in Major Depressive Disorder

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: May 07, 2020

Expiration: May 06, 2021

Rakesh Jain
Rakesh Jain, MD, MPH

Activity

Progress
1
Course Completed

Major depression disorder (MDD) is one of the most common psychiatric disorders that is also associated with heavy physical, psychological, and economic burdens.

In the first module, you learned about how to measure treatment outcomes in people with MDD, what to do when treatments fail, and augmentation of first‑line treatments.

In the comorbidities module, you learned how to assess and approach patients who have physical and psychiatric comorbidities.

In this module, we will review the evidence supporting the use of second-generation antipsychotics for treatment augmentation and how to manage tolerability issues with each approved agent.

The slide thumbnails in this activity link to a complete PowerPoint slideset that can be found here or can be downloaded by clicking any of the thumbnails within the activity.

How many patients with MDD do you provide care for in a typical week?

Your patient with MDD has had partial response after 2 successive trials of antidepressant monotherapy.

If recommending treatment augmentation while following the FDA label, which of the following would you AVOID?

Your patient asks about the relative efficacies of second-generation antipsychotics that are approved by the FDA as adjunctive treatment in MDD. You can tell her that: